| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S40266-015-0291-8 |
| P698 | PubMed publication ID | 26297533 |
| P50 | author | Mauro Zamboni | Q42871092 |
| P2093 | author name string | Andrea Rossi | |
| Andrea P Rossi | |||
| Erika Zanardi | |||
| P2860 | cites work | Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study | Q86396140 |
| Correctly defining criteria for diagnosing chronic obstructive pulmonary disease matters | Q87104474 | ||
| Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease | Q24197989 | ||
| Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease | Q24200446 | ||
| Indacaterol therapy in patients with COPD not receiving other maintenance treatment | Q27010034 | ||
| Measuring the global burden of disease | Q27022594 | ||
| Lung function decline in COPD | Q27024993 | ||
| Inflamm-aging. An evolutionary perspective on immunosenescence | Q28141817 | ||
| Interpretative strategies for lung function tests | Q28279970 | ||
| Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations | Q28389258 | ||
| Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper | Q29614960 | ||
| Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary | Q29614970 | ||
| International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study | Q29614971 | ||
| Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease | Q29618681 | ||
| Deaths: final data for 2009. | Q30833841 | ||
| Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. | Q30872006 | ||
| Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials | Q30933471 | ||
| A comparison of large volume spacer, breath-activated and dry powder inhalers in older people | Q33755748 | ||
| Proportional classifications of COPD phenotypes. | Q33824058 | ||
| Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO) | Q34003435 | ||
| Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease | Q34065677 | ||
| An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease | Q34065958 | ||
| Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study | Q34326181 | ||
| Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis | Q34551086 | ||
| Epidemiology and costs of chronic obstructive pulmonary disease. | Q34563833 | ||
| The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function | Q34568381 | ||
| Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids | Q34641576 | ||
| Active detection of chronic obstructive pulmonary disease and asthma in the general population. Results and economic consequences of the DIMCA program. | Q34755688 | ||
| A 4-year trial of tiotropium in chronic obstructive pulmonary disease | Q34845834 | ||
| Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. | Q35001815 | ||
| Effects of body composition and adipose tissue distribution on respiratory function in elderly men and women: the health, aging, and body composition study | Q35127283 | ||
| Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study | Q35138038 | ||
| Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? | Q43487299 | ||
| How far is real life from COPD therapy guidelines? An Italian observational study | Q43850539 | ||
| Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study | Q43873385 | ||
| Tiotropium versus salmeterol for the prevention of exacerbations of COPD. | Q44248567 | ||
| Risk of osteoporosis in men with chronic bronchitis | Q44876862 | ||
| Inhaled corticosteroids and risk of recurrent pneumonia: a population-based, nested case-control study | Q44981190 | ||
| Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice | Q44984821 | ||
| Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. | Q45915556 | ||
| Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. | Q45939644 | ||
| Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. | Q46035447 | ||
| Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. | Q46562371 | ||
| Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort | Q46785498 | ||
| Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment | Q46919056 | ||
| The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide | Q46966092 | ||
| The impact of COPD on lung health worldwide: epidemiology and incidence | Q47685973 | ||
| Ageing and changes in lung mechanics | Q47716497 | ||
| Pneumonia: still the old man's friend? | Q48615500 | ||
| Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil counts | Q49145139 | ||
| Sex and age differences in pulmonary mechanics in normal nonsmoking subjects. | Q50868619 | ||
| Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. | Q51241641 | ||
| Inhaled steroids in COPD: when should they be used? | Q51680655 | ||
| INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. | Q51687260 | ||
| Competence thresholds for the use of inhalers in people with dementia. | Q52002978 | ||
| Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD | Q55932026 | ||
| Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function | Q57220221 | ||
| Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD | Q57955575 | ||
| Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease | Q57955820 | ||
| Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up | Q57981845 | ||
| Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study | Q58381887 | ||
| Nebulizer vs spacer for bronchodilator delivery in patients hospitalized for acute exacerbations of COPD | Q69384398 | ||
| The course and prognosis of different forms of chronic airways obstruction in a sample from the general population | Q69453259 | ||
| Mechanism of reduced maximal expiratory flow with aging | Q74113205 | ||
| Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison | Q84036383 | ||
| What to use INSTEAD of inhaled corticosteroids in COPD? | Q86082562 | ||
| Blue journal conference. Aging and susceptibility to lung disease | Q35153456 | ||
| Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database | Q35268339 | ||
| Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. | Q35537515 | ||
| Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial | Q35537740 | ||
| Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. | Q35940249 | ||
| Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial | Q36105874 | ||
| The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations | Q36389519 | ||
| The role of bronchodilator treatment in the prevention of exacerbations of COPD. | Q36438669 | ||
| Evaluation of the effectiveness of four different inhalers in patients with chronic obstructive pulmonary disease | Q36572644 | ||
| The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population | Q36835097 | ||
| COPD surveillance--United States, 1999-2011. | Q36999208 | ||
| Inhaled corticosteroids in lung diseases | Q36999789 | ||
| Indacaterol: a comprehensive review | Q37057061 | ||
| Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. | Q37185509 | ||
| Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. | Q37217701 | ||
| Inhaled corticosteroids in COPD and the risk of serious pneumonia | Q37267655 | ||
| Current status of research on osteoporosis in COPD: a systematic review | Q37536544 | ||
| Screening for and early detection of chronic obstructive pulmonary disease | Q37589149 | ||
| Chronic obstructive pulmonary disease in non-smokers | Q37589152 | ||
| Quantification of intermuscular adipose tissue in the erector spinae muscle by MRI: agreement with histological evaluation | Q37612831 | ||
| Therapeutic implications of the pathophysiology of COPD. | Q37700034 | ||
| Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies | Q37878200 | ||
| Pharmacology and therapeutics of bronchodilators | Q38011679 | ||
| Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. | Q38058413 | ||
| Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema | Q38119789 | ||
| The clinical and integrated management of COPD. | Q38211339 | ||
| Inhaled corticosteroids in COPD: the clinical evidence | Q38299453 | ||
| An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. | Q38398677 | ||
| Cigarette smoke and platelet-activating factor receptor dependent adhesion of Streptococcus pneumoniae to lower airway cells. | Q39355357 | ||
| Effects of glucocorticoids on carbohydrate metabolism | Q39631347 | ||
| Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease | Q40393573 | ||
| Aging and the respiratory system | Q41155824 | ||
| Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial | Q42612610 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 679-687 | |
| P577 | publication date | 2015-09-01 | |
| P1433 | published in | Drugs & Aging | Q5308946 |
| P1476 | title | Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids? | |
| P478 | volume | 32 |
| Q58765841 | Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease |
| Q36141290 | Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study. |
| Q92236665 | Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms |
Search more.